Amsterdam

• The effect of Janus Kinase inhibitors on the heart in Rheumatoid Arthritis Pending
  2025-520710-58-00 6 Diagnosis of RA according to the ACR/EULAR 2010 criteria without a his
• A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCL … Pending
  2025-520792-67-00 5 Patients with advanced, metastatic NSCLC that have not progressed on a
• Effectiveness of CBD on behavioural problems in patients with TSC, FXS and Sanfilippo Pending
  2025-520846-31-00 5 Tuberous Sclerosis Complex (TSC), Sanfilippo syndrome, Fragile X syndr
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease Pending
  2025-521154-42-00 4 Sickle Cell Disease
• Clinical trial to assess the safety and tolerability of TP-122A for the treatment of ventilator-associated pneumonia. Pending
  2025-521533-85-00 7 Ventilator-Associated Pneumonia
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial) Pending
  2025-521929-32-01 5 First Episode Psychosis (FEP)
• REVITALISE Study Pending
  2025-522060-32-00 4 STEMI (ST elevated Myocardial Infarction)
• A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small … Pending
  2025-522162-75-00 4 patients with asymptomatic active brain metastases from small cell lun
• OTL-200 Long Term Insertional Oncogenesis Study Pending
  2025-522275-28-00 6 Metachromatic leukodystrophy
• Phase 1/2 study to investigate the safety and preliminary efficacy of GSK5460025 alone or in combination with other anti-cancer agents in dM … Pending
  2025-522318-21-00 7 Neoplasms, Colorectal
• Locating microclots with PET in post-COVID syndrome Pending
  2025-522348-42-00 9 post-COVID syndrome (long COVID)
• Post-INFECT: Investigating Neuroinflammation and its effects in post-COVID syndrome Pending
  2025-522349-23-00 5 post-COVID syndrome
• A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending
  2025-522373-10-00 5 Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
• Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT) Pending
  2025-522404-24-01 10 Lung Cancer
• Pain Relief via Mouthwash or Intravenous Infusion in Mouth Inflammation after Chemotherapy Pending
  2025-522545-22-00 4 Oral mucositis
• A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerabi … Pending
  2025-522582-30-00 1 Alzheimer’s Disease
• Phase 1b Study of VERVE-201 in Patients with Refractory Hyperlipidemia Pending
  2025-522617-39-00 1 Refractory hyperlipidemia
• Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending
  2025-522748-42-00 5 Ovarian cancer
• Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases Pending
  2025-522834-30-01 4 Systemic sclerosis (SSc)
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Urinary Bladder Neoplasms
• Tacrolimus as prophylaxis of post-ERCP pancreatitis Pending
  2025-522900-26-00 6 Post-ERCP Pancreatitis

Showing 49–72 of 1,127 trials